Klotho Neurosciences begins manufacturing of ALS gene therapy KLTO-202, targeting Phase I/II start by Q3 2026

Greenland Mines Ltd

KLTO-202 gene therapy manufacturing underway; process development & manufacturing expected to take approx. 8 months.
Company targets FDA meetings, animal safety studies, IND filing, and Phase I/II trial start by Q3 2026.
Therapy uses s-KL RNA splice variant of alpha-Klotho gene licensed from Autonomous University of Barcelona.
Animal studies in ALS, Alzheimer's, and aging models showed favorable therapeutic outcomes.
Company will use CROs to manage manufacturing and clinical trials, avoiding large staff increases.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.